Rhumbline Advisers Has $42.26 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Rhumbline Advisers decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 179,578 shares of the biopharmaceutical company’s stock after selling 1,850 shares during the quarter. Rhumbline Advisers owned 0.14% of Alnylam Pharmaceuticals worth $42,256,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ALNY. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $61,160,000. Strategic Financial Concepts LLC acquired a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $41,529,000. Los Angeles Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after buying an additional 135,829 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after buying an additional 2,285 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in Alnylam Pharmaceuticals by 3.0% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after acquiring an additional 8,462 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. This trade represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 73,964 shares of company stock valued at $20,622,925 in the last 90 days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ALNY. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Sanford C. Bernstein reduced their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Chardan Capital reiterated a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $299.43.

Alnylam Pharmaceuticals Trading Down 3.2 %

Shares of Alnylam Pharmaceuticals stock opened at $256.45 on Tuesday. The company has a market capitalization of $33.08 billion, a P/E ratio of -97.88 and a beta of 0.35. The stock has a fifty day simple moving average of $254.04 and a 200 day simple moving average of $263.44. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.